What Doctamine Treats: Main Uses and Benefits

Doctamine (Butamirate Citrate) is a therapeutic option commonly used for the symptomatic relief of coughs that are non-productive, or dry, and is often characterized by persistence. Its use is applied to ease the impact of an irritating cough reflex that is dry, thereby contributing to improved patient comfort across several common clinical scenarios. The medication is relevant for easing symptoms related to physical discomfort associated with dry, irritant coughs of various etiologies.

This medication is used for managing symptoms that appear suddenly or fluctuate, including those linked to acute respiratory conditions like tracheitis, laryngitis, or acute bronchitis. It is also applied in clinical settings that involve acute or unstable symptom patterns, such as providing supportive relief for the severe, episodic coughing spasms of whooping cough and for pre- and post-operative cough suppression.

“The goal of this medication is to reduce the frequency and intensity of persistent coughing, which supports the patient during difficult episodes by easing distress.”

By providing relief, Doctamine helps maintain a sense of stability when symptoms are more noticeable, assists with maintaining functional stability and provides support that helps ease the overall symptom burden.

---

Quick Fact: Relief for Irritable Dry Cough

---

Regulatory References

1. Philippines FDA Patient Information Leaflet

Who Can and Cannot Use Doctamine?

Eligibility for Doctamine (Butamirate Citrate) is strictly defined by regulatory label information, classifying specific populations as eligible, restricted, or contraindicated.

Category	Official Regulatory Status
Populations for whom use is allowed	Adults and Adolescents are generally eligible for use under standard labeled conditions for dry cough relief.
Populations for whom use is contraindicated	Patients with known Hypersensitivity to Butamirate Citrate or any of the product's excipients. Individuals with rare hereditary problems of Fructose Intolerance (applies to syrup formulations containing sorbitol).
Age-related eligibility rules	Contraindicated in children under a specified minimum age, which varies by country and formulation (often under 3 or 6 years). Use in other younger pediatric groups may be not recommended.
Pregnancy and lactation eligibility	Contraindicated or Not Recommended during the First Trimester of Pregnancy. Use is restricted and permitted only if absolutely necessary during the second and third trimesters. Not Recommended during Lactation (breastfeeding).
Eligibility-related restrictions	Use must be avoided simultaneously with expectorants to prevent the risk of mucus accumulation. Caution is often required due to lack of established data in patients with impaired renal or hepatic function.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Doctamine (Butamirate Citrate) based strictly on governmental regulatory information.

The regulatory profile imposes specific prohibitions and restrictions based on documented pharmacokinetic (PK) and pharmacodynamic (PD) interaction risks.

Official Interaction Statements and Restrictions

Category	Interacting Substance/Class	Official Regulatory Constraint
Pharmacodynamic	Expectorants (Mucus Clearance Agents)	Co-administration is prohibited. The combined effect can cause mucus to accumulate in the airways, increasing the risk of respiratory infection or bronchospasm.
Pharmacokinetic	Strong Enzyme Inhibitors	Co-administration is prohibited. There is a possible risk of increased systemic exposure of Butamirate Citrate.
Pharmacokinetic	Medicines with a Narrow Therapeutic Index	Co-administration is prohibited. There is a possible risk of altered exposure of the co-administered drug.
Pharmacodynamic	Alcohol (Ethanol)	Use should be limited or avoided. Alcohol may enhance central nervous system (CNS) depressant effects, which can result in increased drowsiness.

Clearance and Population Notes

The regulatory profile notes that patients with hepatic or renal impairment may face a greater risk of adverse effects. This is related to the internal pharmacokinetic profile, specifically the potential for drug and metabolite accumulation due to reduced clearance.

How Doctamine Works

Doctamine operates through selective receptor- or enzyme-mediated signaling within specific biological systems. Its primary action involves the precise modulation of distinct signaling patterns. This mechanism influences intracellular cascades characterized by multiple layers of pathway activation, resulting in an altered profile of physiological output by modulating signaling input.

---

Receptor- or Enzyme-Mediated Signaling

The compound functions via direct interaction as an antagonist at specific cellular receptors, or as an inhibitor of target enzymes. This engagement modifies the early molecular steps of the sequence by either suppressing the initiation of downstream signals or reducing the concentration of available mediator activity.

---

Modulation of Heightened Signaling Pathways

Doctamine interacts with pathways characterized by heightened or irregular signaling activity, serving to alter pathway activity that may escalate under certain conditions. This engagement results in an alteration of physiological parameters governed by targeted pathways, adjusting system response thresholds to influence the overall physiological state.

Official Administration Guidelines for Doctamine (Dopamine HCl)

Doctamine (Dopamine HCl) is administered only as a continuous intravenous (IV) infusion and must be strictly managed in a clinical setting. Oral, intramuscular, or subcutaneous routes are not approved.

Dosing and Administration Protocol

Administration Component	Regulatory Instruction
Route & Delivery	Continuous IV infusion only, using an infusion pump.
Standard Initial Dose	2 to 5 mcg/kg/minute for both adults and pediatrics.
Dose Adjustment	The infusion rate is continuously titrated in increments of 5 to 10 mcg/kg/minute based on the patient's real-time response.
Maximum Rate	The infusion rate should generally not exceed 50 mcg/kg/minute.

Preparation and Handling Requirements

Dilution: The concentrated solution must always be diluted prior to use with an approved IV fluid, such as 0.9% Sodium Chloride or 5% Dextrose Injection. It is critical not to mix the drug with alkaline solutions, such as Sodium Bicarbonate, as this can lead to inactivation of the product. Solutions must be inspected before use and should be clear and colorless to slightly yellow; solutions that are discolored or contain particulate matter must not be administered.

Special Dosing Rules: Patients who have recently received a Monoamine Oxidase (MAO) inhibitor within two to three weeks must start at a substantially reduced dose, specifically one-tenth of the usual starting dose. The infusion must be introduced into a large vein to minimize the risk of tissue damage (extravasation).

Research Evidence / Overview of Studies for Doctamine (Butamirate Citrate)

Research has explored how Doctamine (Butamirate Citrate) was evaluated in studies related to dry, irritative cough, a condition characterized by fluctuating or episodic manifestations. The research landscape includes primarily Randomized Controlled Trials (RCTs) and specialized Human Cough Challenge Studies that focus on understanding short-term symptom patterns.

Evidence for Symptomatic Relief of Dry, Irritative Cough

Research examined how Butamirate Citrate was evaluated in trials exploring symptoms related to systemic or functional imbalance associated with cough. These studies primarily focused on adult patients experiencing irritative cough, including those linked to conditions associated with acute or disruptive episodes. The researchers examined key factors, including patient-reported outcomes describing perceived discomfort (cough frequency and severity) and objective measurement of the cough reflex threshold.

In these trials, findings describe patterns observed in the studies related to how symptoms evolved. Human Challenge Studies were applied in research contexts to explore changes in the cough reflex threshold; however, the data show patterns related to reflex sensitivity that were mixed and not always consistent. Overall, the evidence contributes to understanding short-term symptom patterns in patients with irritative cough.

Studies Comparing Doctamine to Other Agents

Butamirate Citrate was studied for comparisons against both an inactive substance (placebo) and active comparator medicines in research settings. Findings from some comparative studies show patterns related to short-term changes observed in the populations studied. However, comparative evidence is limited regarding the full range of alternative agents.

Long-Term Evidence and Follow-up Duration

Clinical trials assessing the primary effects of Doctamine were evaluated in trials assessing short-term or episodic symptom patterns, with follow-up durations limited to typically less than one week. Due to this focus, there is limited information for long-term outcomes or the consequences of prolonged use, and the durability of any observed patterns beyond the study period is not fully established.

What Research Gaps and Uncertainty Remain

Several limitations in the current body of research have been identified, including the high rate of spontaneous remission and the large placebo effect observed in acute cough, which presents a challenge in isolating specific drug-related findings. Furthermore, subgroup findings are uncertain regarding consistency across patient groups, and the results apply only to the populations studied.

Common questions about Doctamine (FAQ)

---

Q: How quickly does Doctamine usually start working after the first dose?

Official information states that the active ingredient in Doctamine is rapidly absorbed after being taken orally. Studies indicate that the active ingredient is rapidly absorbed, with the cough-suppressing effect generally commencing within approximately 30 minutes after the first dose.

Q: Can Doctamine be used by people who have existing liver problems?

Regulatory caution is advised, as official information states data is lacking for patients with impaired hepatic (liver) function. Patients with reduced liver function may face a greater risk of adverse effects due to the accumulation of the medicine in the body.

Q: Are there any common foods or drinks that should be avoided while taking Doctamine?

Regulatory information on interactions primarily focuses on other medicines and alcohol. The official guidance recommends limiting or avoiding alcohol consumption because it may enhance the medicine's CNS depressant effects, potentially leading to increased drowsiness. No specific common food interactions are documented in the official labeling.

Q: Is there a generic version of Doctamine available?

Yes, the active ingredient in Doctamine is Butamirate Citrate. This is the generic name for the substance. The medicine is sold under various brand names, and the generic name is often available in different markets worldwide.

Q: Can people with kidney disease be prescribed Doctamine?

Official prescribing information advises regulatory caution, as official data is not fully established for this population. This caution is related to the potential for the medicine and its metabolites to accumulate due to reduced clearance, which could increase the risk of adverse effects.

Q: Why is Doctamine not suitable for children under a certain age?

Official labeling consistently states that the medicine is contraindicated, or not recommended, for young children, often those under three years old. This restriction is based on safety concerns and a lack of established efficacy data for that specific age group.

Q: Does Doctamine have a risk of addiction or dependence?

Doctamine is classified as a non-narcotic, centrally acting antitussive. Regulatory documents specify that it is not chemically or pharmacologically related to opioid alkaloids. This classification indicates that the substance does not produce undesirable effects such as addiction.

Q: What are the signs of a rare but serious side effect of Doctamine?

The most clinically notable serious risk documented in official safety profiles is a hypersensitivity reaction, which is an allergic response. Examples of signs of this rare reaction, based on safety documentation, include rash, itching, swelling, severe dizziness, or difficulty breathing.

Q: What is the main difference between Doctamine and other similar medicines?

The primary functional difference described in official documents is its pharmacological class. Doctamine (Butamirate Citrate) is a non-opioid, centrally acting antitussive. This mechanism distinguishes it from narcotic cough suppressants because it works on the cough center without being chemically related to opioid alkaloids.

Q: Is Doctamine considered a prescription-only medicine?

The legal status of Doctamine's active ingredient, Butamirate Citrate, varies by region. It is often classified internationally as an Over-the-Counter (OTC) medicine, meaning it may be available without a prescription in many areas.

Q: Do I need to take Doctamine at a specific time of day?

Official dosing instructions emphasize taking the medicine at regular intervals to maintain a consistent effect, such as three to four times daily. However, regulatory information does not specify a mandatory time of day for the first dose or subsequent doses.

Q: Is it normal to feel a mild headache when starting Doctamine?

Headache has been reported in post-market surveillance or less common clinical findings. While not always included in the official 'Rare' list of side effects in all regulatory documents, it is an effect that has been noted in safety surveillance.

Q: Does Doctamine interact with common over-the-counter pain relievers like ibuprofen?

Official regulatory information states that there are no known significant drug interactions between Butamirate Citrate and most general medicines, including common OTC pain relievers. However, the label does include a warning against its use with strong enzyme inhibitors or medicines that have a narrow therapeutic index.

Q: Does Doctamine affect blood pressure or heart rate?

Official regulatory documents do not list blood pressure or heart rate changes as common or rare side effects. However, in cases of accidental overdose, hypotension (low blood pressure) is listed as a potential symptom, which suggests a potential effect on cardiovascular parameters at concentrations resulting from overdose.

Q: What is the typical half-life of Doctamine in the body?

The medicine's effect is temporary, as its apparent elimination half-life is approximately 6 hours. This half-life refers to the time it takes for half of the principal active metabolite to be cleared from the system. This is a key pharmacokinetic fact noted in regulatory documents.

Q: Can I use common cold medicines or flu remedies while taking Doctamine?

Official labeling advises against taking Doctamine with expectorants, which are often found in cold and flu remedies, because this combination can cause mucus accumulation. Additionally, caution is advised regarding its use with other central nervous system (CNS) depressants, which may also be present in multi-symptom cold and flu preparations.

Q: How soon after stopping Doctamine will the medicine be completely out of my system?

The elimination time is determined by the medicine's half-life, which is approximately 6 hours for the principal active metabolite. Based on this figure, the medicine is generally predicted to be mostly eliminated from the body within approximately 30 hours after the last dose.

Q: What is the legal classification of Doctamine internationally (e.g., in Europe or Canada)?

Butamirate Citrate is commonly available internationally, and its regulatory status is often classified as an Over-the-Counter (OTC) antitussive. However, it is important to know that the exact legal classification and availability may differ between countries.

Q: What is the physical appearance of the Doctamine medication (e.g., color, shape)?

Official regulatory documents must specify the available forms, such as syrup, drops, or tablets, and the type of packaging used. However, these documents do not consistently detail the specific physical appearance of the drug product, such as the color or shape of the tablet or liquid.

Official Storage and Disposal Requirements

Storage of Doctamine (Butamirate Citrate) must strictly adhere to regulatory labeling to maintain product quality and safety. The medicine should be stored below 25 C and protected from light. It is mandatory that the product not be refrigerated or frozen.

To ensure integrity, the medicine must be stored in the original container, kept tightly closed, and always secured out of the sight and reach of children.

Liquid formulations must be discarded 6 months after the initial opening regardless of the printed expiry date. Unused or expired Doctamine must not be disposed of in household waste or via wastewater. Instead, the medicine should be returned to a pharmacy or disposal facility according to local regulations.